Novo Nordisk Investor Presentation - First Nine Months of 2016

Investor presentation First nine months of 2016 Slide 83 SaxendaⓇ targeted at patients with BMI ≥35 and weight-related comorbidities SaxendaⓇ market approach Clear patient segmentation Focused prescriber targeting SaxendaⓇ launch execution Focus on patients with BMI ≥35 with weight-related comorbidities Focus on current prescribers of anti-obesity medication and GLP-1 Aspiration Clear product value proposition Focus on engaging prioritised payers and employers Strengthened by 3-year clinical data Formulary coverage emerging with more than 50 million lives¹ covered BMI: body mass index 1 Potential lives covered, based on employer opt-ins changing diabetes Build the market novo nordisk

View entire presentation